Sector News

Regeneron doubles investment, adding 200 more jobs to plant in Ireland

October 19, 2015
Life sciences

Flourishing and flush with cash, Regeneron is on a building and hiring spree. Today the drugmaker says it will more than double its investment and hire an additional 200 workers at a plant still under construction in Ireland.

That comes even as it is adding space to its campus in Tarrytown, NY, where it expects its headcount this year to grow by 1,000.

Regeneron is converting a former Dell computer plant in Limerick, Ireland, into its first production facility outside of the U.S. What started out as a $300 million project needing 300 workers is morphing into a $650 million project that will require 500 workers, according to the Ireland Development Authority (IDA), which is helping support the project. Officials say the facility will be the largest biopharma plant in the country when it is complete at the end of 2017.

“With a growing portfolio of marketed medicines and an innovative pipeline rooted in cutting-edge science and technology, Regeneron is one of the fastest-growing global biopharmaceutical companies,” Regeneron CEO Leonard Schleifer said in a statement. He said the Limerick facility will be essential to the drugmaker’s expansion.

So far that expansion has been fueled by sales of Regeneron’s eye drug Eylea which helped the company see a 50% growth in revenue in the second quarter to just shy of $1 billion. It has an FDA approval in the bag for Praluent, one of a new class of PCSK9 cholesterol drugs which it developed with Sanofi ($SNY) and a pipeline of promising meds.

To support that pipeline work, the drugmaker is also rapidly expanding at its campus in New York. It is expecting to have added 1,000 employees there this year, bringing the headcount to 4,000, from 3,000 at the end of 2014 and 2,300 at the end of 2013. To house all of those people it has added 116,200 square feet of office/lab space to its lease at the Landmark at Eastview research campus in Tarrytown, NY, about 30 minutes from Manhattan. That boosts its campus to 1.1 million square feet.

Regeneron’s boom times stand in stark contrast to Japan-based Daiichi Sankyo, which reportedly is whacking up to 1,200 jobs in the U.S., about half its workforce in its stateside subsidiary. That comes as the drugmaker repositions itself in the face of the impending patent loss on its blood pressure drug Benicar. Its $2.6 billion in sales last year added up to more than 25% of the drugmaker’s revenue.

By Eric Palmer

Source: Fierce Pharma

comments closed

Related News

March 2, 2024

Seeking blockbuster status, UCB eyes 4 new indications for psoriasis med Bimzelx in 2024

Life sciences

After 14 regulatory approvals on three continents last year, UCB is positioned to grow for “a decade-plus,” CEO Jean-Christophe Tellier said in the company’s full-year earnings press release. Meanwhile, eight regulatory reviews are ongoing.

March 2, 2024

Argenx goes again, ramping up unbranded campaign ahead of hoped-for label expansion

Life sciences

Vyvgart Hytrulo, the subcutaneous version of argenx’s FcRn blocker, is already approved in generalized myasthenia gravis (gMG). Supported by data published last year, the biotech has filed for approval in a second setting, chronic inflammatory demyelinating polyneuropathy (CIDP), and is now counting down the weeks until the FDA rules on its submission.

March 2, 2024

EuroAPI appoints new CEO and lays out restructuring plan as manufacturer’s losses mount

Life sciences

Overseeing the four-year plan, dubbed FOCUS-27, will be new chief executive officer Ludwig de Mot—an industry veteran with a track record at “companies undergoing transformation,” EuroAPI said in an earnings release Wednesday. De Mot, who will take up the reins on Friday, joined the company in January as EuroAPI’s chief transformation officer.

How can we help you?

We're easy to reach